Health Care [ 9/12 ] | Pharmaceuticals [ 36/76 ]
NASDAQ | Common Stock
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally.
The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old.
It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency.
The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021.
Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 24 | -0.52 Increased by +73.06% | -0.64 Increased by +18.75% |
| Feb 14, 24 | -0.04 Increased by +96.95% | -0.25 Increased by +84.00% |
| Nov 14, 23 | -1.48 Decreased by -23.33% | -0.04 Decreased by -3.60 K% |
| Sep 27, 23 | -0.59 Increased by +93.98% | -0.95 Increased by +37.89% |
| May 11, 23 | -1.93 Increased by +94.61% | -0.63 Decreased by -206.35% |
| Feb 21, 23 | -1.31 Increased by +85.11% | -1.60 Increased by +18.13% |
| Nov 14, 22 | -1.20 Increased by +94.50% | -3.60 Increased by +66.67% |
| Sep 27, 22 | -9.80 Increased by +34.67% | -7.40 Decreased by -32.43% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 17.98 M Decreased by -41.51% | -4.62 M Decreased by -88.03% | Decreased by -25.70% Decreased by -221.47% |
| Mar 31, 24 | 17.99 M Decreased by -20.85% | -2.89 M Increased by +50.53% | Decreased by -16.06% Increased by +37.50% |
| Dec 31, 23 | 22.93 M Decreased by -12.73% | -220.00 K Increased by +97.88% | Decreased by -0.96% Increased by +97.57% |
| Sep 30, 23 | 22.10 M Decreased by -20.09% | -8.12 M Decreased by -91.65% | Decreased by -36.74% Decreased by -139.83% |
| Jun 30, 23 | 30.73 M Increased by +11.96% | -2.46 M Increased by +93.54% | Decreased by -7.99% Increased by +94.23% |
| Mar 31, 23 | 22.73 M Decreased by -6.06% | -5.84 M Increased by +95.83% | Decreased by -25.70% Increased by +95.57% |
| Dec 31, 22 | 26.28 M Increased by +13.64% | -10.39 M Increased by +10.03% | Decreased by -39.54% Increased by +20.83% |
| Sep 30, 22 | 27.66 M Increased by +26.30% | -4.24 M Increased by +84.79% | Decreased by -15.32% Increased by +87.95% |